Jo C. Dumville

Jo C. Dumville

Auto-generated profile, based on publicly available information

Jo C. Dumville

Division of Nursing, Midwifery and Social Work, School of Health Sciences, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2005 in BMJ
Verified
Journal Article
Closed access
PDF file
JPJill Porthouse
Jill Porthouse
SCSarah Cockayne
Sarah Cockayne
CKChristine King
Christine King
LSLucy Saxon
Lucy Saxon
ESElizabeth Steele
Elizabeth Steele
DTDavid J Torgerson
David J Torgerson
Objective To assess whether supplementation with calcium and cholecaliferol (vitamin D3) reduces the risk of fracture in women with one or more risk factors for fracture of the hip. Design Pragmatic open randomised controlled trial. Setting Practice nurse led clinics in primary care. Participants 3314 women aged 70 and over with one or more risk factors for hip fracture: any previous fracture, low body weight (< 58 kg), smoker, family history of hip fracture, or fair or poor self reported health. Intervention Daily oral supplementation using 1000 mg calcium with 800 IU cholecaliferol and information leaflet on dietary calcium intake and prevention of falls, or leaflet only (control group). Main outcome measures Primary outcome measure was all clinical fractures and secondary outcome measures were adherence to treatment, falls, and quality of life (measured with the SF-12). Results 69% of the women who completed the follow-up questionnaire at 24 months were still taking supplements (55% with inclusion of randomised participants known to be alive). After a median follow-up of 25 months (range 18 to 42 months), clinical fracture rates were lower than expected in both groups but did not significantly differ for all clinical fractures (odds ratio for fracture in supplemented group 1.01, 95% confidence interval 0.71 to 1.43). The odds ratio for hip fracture was 0.75 (0.31 to 1.78). The odds of a woman having a fall at six and 12 months was 0.99 and 0.98, respectively. Quality of life did not significantly differ between the groups. Conclusion We found no evidence that calcium and vitamin D supplementation reduces the risk of clinical fractures in women with one or more risk factors for hip fracture. Registration ISRCTN26118436, controlled trials registry.

20 April 2006 in BMJ
Verified
Journal Article
Closed access
PDF file
JDJo C Dumville
Jo C Dumville
DTDavid J Torgerson
David J Torgerson
CHCatherine E Hewitt
Catherine E Hewitt
Effects of attrition Attrition can introduce bias if the characteristics of people lost to follow-up differ between the randomised groups. In terms of bias, this loss is important only if the differing characteristic is correlated with the trial's outcome measures. However, attrition is not a black and white issue—there is no specific level of loss to follow-up at which attrition related bias becomes acknowledged as a problem. Schulz and Grimes argue that loss to follow-up of 5% or lower is usually of little concern, whereas a loss of 20% or greater means that readers should be concerned about the possibility of bias; losses between 5% and 20% may still be a source of bias.3 For the purposes of this article we will not differentiate between loss to follow-up and missing data. We have also not considered exclusions by trial investigators. Although exclusion is justified in some cases,3 generally it is ill advised.1 2

1 February 2006 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
JDJ.C. Dumville
J.C. Dumville
SHS. Hahn
S. Hahn
JMJ.N.V. Miles
J.N.V. Miles
DTD.J. Torgerson
D.J. Torgerson

6 March 2015 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
AJAndrew B Jull
Andrew B Jull
NCNicky Cullum
Nicky Cullum
JDJo C Dumville
Jo C Dumville
MWMaggie J Westby
Maggie J Westby
SDSohan Deshpande
Sohan Deshpande
NWNatalie Walker
Natalie Walker

19 March 2009 in BMJ
Verified
Journal Article
Open access
PDF file
JDJo C Dumville
Jo C Dumville
GWGill Worthy
Gill Worthy
JBJ Martin Bland
J Martin Bland
NCNicky Cullum
Nicky Cullum
CDChristopher Dowson
Christopher Dowson
DTDavid J Torgerson
David J Torgerson
Objective To compare the clinical effectiveness of larval therapy with a standard debridement technique (hydrogel) for sloughy or necrotic leg ulcers. Design Pragmatic, three armed randomised controlled trial. Setting Community nurse led services, hospital wards, and hospital outpatient leg ulcer clinics in urban and rural settings, United Kingdom. Participants 267 patients with at least one venous or mixed venous and arterial ulcer with at least 25% coverage of slough or necrotic tissue, and an ankle brachial pressure index of 0.6 or more. Interventions Loose larvae, bagged larvae, and hydrogel. Main outcome measures The primary outcome was time to healing of the largest eligible ulcer. Secondary outcomes were time to debridement, health related quality of life (SF-12), bacterial load, presence of meticillin resistant Staphylococcus aureus, adverse events, and ulcer related pain (visual analogue scale, from 0 mm for no pain to 150 mm for worst pain imaginable). Results Time to healing was not significantly different between the loose or bagged larvae group and the hydrogel group (hazard ratio for healing using larvae v hydrogel 1.13, 95% confidence interval 0.76 to 1.68; P=0.54). Larval therapy significantly reduced the time to debridement (2.31, 1.65 to 3.2; P<0.001). Health related quality of life and change in bacterial load over time were not significantly different between the groups. 6.7% of participants had MRSA at baseline. No difference was found between larval therapy and hydrogel in their ability to eradicate MRSA by the end of the debridement phase (75% (9/12) v 50% (3/6); P=0.34), although this comparison was underpowered. Mean ulcer related pain scores were higher in either larvae group compared with hydrogel (mean difference in pain score: loose larvae v hydrogel 46.74 (95% confidence interval 32.44 to 61.04), P<0.001; bagged larvae v hydrogel 38.58 (23.46 to 53.70), P<0.001). Conclusions Larval therapy did not improve the rate of healing of sloughy or necrotic leg ulcers or reduce bacterial load compared with hydrogel but did significantly reduce the time to debridement and increase ulcer pain. Trial registration Current Controlled Trials ISRCTN55114812 and National Research Register N0484123692.

29 November 2017 in Implementation Science
Verified
Journal Article
Open access
PDF file
JLJacqueline F. Lavallée
Jacqueline F. Lavallée
TGTrish A. Gray
Trish A. Gray
JDJo Dumville
Jo Dumville
WRWanda Russell
Wanda Russell
NCNicky Cullum
Nicky Cullum
Care bundles are a set of three to five evidence-informed practices performed collectively and reliably to improve the quality of care. Care bundles are used widely across healthcare settings with the aim of preventing and managing different health conditions. This is the first systematic review designed to determine the effects of care bundles on patient outcomes and the behaviour of healthcare workers in relation to fidelity with care bundles. This systematic review is reported in line with the PRISMA statement for reporting systematic reviews and meta-analyses. A total of 5796 abstracts were retrieved through a systematic search for articles published between January 1, 2001, to February 4, 2017, in the Cochrane Central Register for Controlled Trials, MEDLINE, EMBASE, British Nursing Index, CINAHL, PsychInfo, British Library, Conference Proceeding Citation Index, OpenGrey trials (including cluster-randomised trials) and non-randomised studies (comprising controlled before-after studies, interrupted time series, cohort studies) of care bundles for any health condition and any healthcare settings were considered. Following the removal of duplicated studies, two reviewers independently screen 3134 records. Three authors performed data extraction independently. We compared the care bundles with usual care to evaluate the effects of care bundles on the risk of negative patient outcomes. Random-effect models were used to further explore the effects of subgroups. In total, 37 studies (6 randomised trials, 31 controlled before-after studies) were eligible for inclusion. The effect of care bundles on patient outcomes is uncertain. For randomised trial data, the pooled relative risk of negative effects between care bundle and control groups was 0.97 [95% CI 0.71 to 1.34; 2049 participants]. The relative risk of negative patient outcomes from controlled before-after studies favoured the care bundle treated groups (0.66 [95% CI 0.59 to 0.75; 119,178 participants]). However, using GRADE, we assessed the certainty of all of the evidence to be very low (downgraded for risk of bias, inconsistency, indirectness). Very low quality evidence from controlled before-after studies suggests that care bundles may reduce the risk of negative outcomes when compared with usual care. By contrast, the better quality evidence from six randomised trials is more uncertain. PROSPERO, CRD42016033175